ArticleBreast cancer research and treatment2019
Mammographic screening in male patients at high risk for breast cancer: is it worth it?
Article in Breast cancer research and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Male Breast Cancer: Growing Insights and Continuing Challenges.Cancer medicine · 2026Review
- [Use of imaging methods in the current screening, diagnostics and treatment of breast cancer - Professional guidelines. 5th Breast Cancer Consensus Meeting (2025)].Magyar onkologia · 2025Article
- BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.JAMA oncology · 2024Review
- Mammographically and sonographically occult male DCIS seen only on breast MRI.Radiology case reports · 2024Article
- Male Breast Cancer: Imaging Considerations for Diagnosis and Surveillance.Journal of clinical medicine research · 2024Review
- Radiological Features of Male Breast Neoplasms: How to Improve the Management of a Rare Disease.Diagnostics (Basel, Switzerland) · 2024Article
- Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship.Current oncology reports · 2024Review
- Male breast: An unusual case of metastasis of squamous cell carcinoma of the skin.Radiology case reports · 2023Article
- A Prospective Population-Based Study of Cardiovascular Disease Mortality following Treatment for Breast Cancer among Men in the United States, 2000-2019.Current oncology (Toronto, Ont.) · 2022Article
- Male breast cancer: an update.Virchows Archiv : an international journal of pathology · 2022Review
- Use of Diagnostic Imaging Modalities in Modern Screening, Diagnostics and Management of Breast Tumours 1st Central-Eastern European Professional Consensus Statement on Breast Cancer.Pathology oncology research : POR · 2022Review
- Male Breast Cancer Review. A Rare Case of Pure DCIS: Imaging Protocol, Radiomics and Management.Diagnostics (Basel, Switzerland) · 2021Article
- Genetic Landscape of Male Breast Cancer.Cancers · 2021Review
- Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).JAMA oncology · 2020Article
- Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer.International journal of molecular sciences · 2020Article
- Image-based screening for men at high risk for breast cancer: Benefits and drawbacks.Clinical imaging · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 5 countries.
Funding
Abstract
purposeTo investigate the utility of mammography for breast cancer screening in a population of males at increased risk for breast cancer.
methodsIn this HIPAA-compliant institutional review board-approved single-institution study, mammography records and clinical data of 827 male patients who underwent digital mammography from September 2011-July 2018 were analyzed via the electronic medical record. 664 of these men presented with masses, pain, or nipple discharge and were excluded from this study. The remaining 163 asymptomatic men with familial and/or personal history of breast cancer, or with a known germline mutation in BRCA, underwent screening mammography and were included in this analysis.
results163 asymptomatic men (age: mean 63 years, range 24-87 years) underwent 806 screening mammograms. 125/163 (77%) had a personal history of breast cancer and 72/163 (44%) had a family history of breast cancer. 24/163 (15%) were known mutation carriers: 4/24 (17%) BRCA1 and 20/24 (83%) BRCA2. 792/806 (98%) of the screening mammograms were negative (BI-RADS 1 or 2); 10/806 (1.2%) were classified as BI-RADS 3, all of which were eventually downgraded to BI-RADS 2 on follow-up. 4/806 (0.4%) mammograms were abnormal (BI-RADS 4/5): all were malignant. The cancer detection rate in this cohort was 4.9 cancers/1000 examinations.
conclusionsIn our cohort, screening mammography yielded a cancer detection rate of 4.9 cancers/1000 examinations which is like the detection rate of screening mammography in a population of women at average risk, indicating that screening mammography is of value in male patients at high risk for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.